Biotech Investors: Mark Your 2005 Calendars

Successful biotech investors stay on top of the calendar, because they need to be proactive about clinical data and Food and Drug Administration action dates. Regular readers have had an insatiable appetite for previous biotech catalyst calendars, so here's my latest for 2005. It's not comprehensive, and some of the dates are approximations, but this should give biotech investors a good road map for the upcoming year.

FDA Approvals/Filing Dates

American Pharmaceutical Partners (APPX:Nasdaq - news - research): Abraxane, breast cancer, Jan. 8, 2005;
Cyberonics (CYBX:Nasdaq - news - research): VNS Therapy System, depression, Jan. 31, 2005;
Discovery Labs (DSCO:Nasdaq - news - research): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;
Millennium Pharmaceuticals (MLNM:Nasdaq - news - research): Velcade, second-line multiple myeloma, March 29, 2005;
Celgene (CELG:Nasdaq - news - research): Revlimid, FDA filing for myelodysplastic syndrome (5 q minus), first quarter 2005. Revlimid, multiple myeloma phase III, second half 2005;
Cephalon (CEPH:Nasdaq - news - research): Nuvigil, narcolepsy, sleep apnea, shift work sleep disorder FDA filing, first quarter 2005;
Amylin Pharmaceuticals (AMLN:Nasdaq - news - research): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005;
More...